How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Policy 0070 is a ground-breaking initiative and the European Medicines Agency (EMA) represents the first agency on a global level that will grant access to clinical trial data on such a large scale. With the requirements for all non-Covid products expected to restart in 2023, there is preparation required for qualifying submissions – which include new marketing authorization applications (MAAs) and clinical variations.
Related Insights
Video
Oncology experts roundtable: Practical insights on FDA draft guidance discussing OS data in cancer trials
Oct 24, 2025
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Related Insights
Video
Oncology experts roundtable: Practical insights on FDA draft guidance discussing OS data in cancer trials
Oct 24, 2025
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023